VYNE Therapeutics

A clinical-stage biopharmaceutical company focused on developing therapies to treat chronic inflammatory and immune-mediated conditions.

Health Tech & Life Sciences
Acquired by Menlo Therapeutics
Public Ness Ziona, Israel Founded 2003
Last updated 2026-07-20
Total raised
$80.0M
Last: Undisclosed Round 2019-07
Stage
Public
Founded
2003
Headcount
125
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences

About

VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions.

VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology and has received FDA approval for AMZEEQ (minocycline) topical foam, 4%, a topical minocycline; and ZILXI (minocycline) topical foam, 1.5%, a minocycline product for the treatment of rosacea.

The company was formed from the merger of Foamix, an Israeli clinical-stage specialty pharmaceutical company, and Menlo Therapeutics, a US-based dermatology company.

Funding history · 4 rounds · $80.0M total

2019-06
PIPE $64.0M
★ OrbiMed★ Perceptive Advisors
2018-03
PIPE $16.0M
★ OrbiMed
2015-03
Follow-on PO Undisclosed
2014-08
Follow-on PO Undisclosed

Headcount over time

From 78 (2019-02) to 49 (2026-03) · -29 (-37%) · 23 points · source: Finder history + radar grounding
1500 2019-02 2026-03

Q&A

What is VYNE Therapeutics' primary focus?
VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions.
Which products has VYNE Therapeutics received FDA approval for?
VYNE Therapeutics has received FDA approval for AMZEEQ (minocycline) topical foam, 4%, a topical minocycline; and ZILXI (minocycline) topical foam, 1.5%, a minocycline product for the treatment of rosacea.
When was VYNE Therapeutics formed and how?
VYNE Therapeutics was formed in November 2019 from the merger of Foamix, an Israeli clinical-stage specialty pharmaceutical company, and Menlo Therapeutics, a US-based dermatology company.
What was the last funding round for VYNE Therapeutics?
VYNE Therapeutics' last funding round was in July 2019, raising $64,000,000 from investors including Perceptive Advisors and OrbiMed.
What is the employee count for VYNE Therapeutics?
VYNE Therapeutics has 51-200 employees.
Who is the founder of Foamix Pharmaceuticals, which merged to form VYNE Therapeutics?
Meir Eini is the Founder of Foamix Pharmaceuticals.
What is the current status of VYNE Therapeutics?
VYNE Therapeutics is currently listed as acquired and inactive, having been acquired by Menlo Therapeutics in November 2019.
What is VYNE Therapeutics' total amount raised in funding?
VYNE Therapeutics has raised a total of $180,000,000 USD.

Team · 1

Founder · Founder - Foamix Pharamecutials
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 Patents

Tags

skin-caredermatologytopical-treatmentacnepharmaceuticalstreatmentspharma-companiespatientsinflammatory-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitewww.vynetherapeutics.com
LinkedInlinkedin.com/company/68042510
Facebookfacebook.com/VYNEtx
Wikidatawikidata.org/wiki/Q104480752

Identifiers & details

Legal nameVYNE Therapeutics Inc.
Former namesFoamix Pharmaceuticals, Menlo Therapeutics
Founded2003-1
Employees (exact)125
OfficesBridgewater Township
Market cap$19.3M
Status reasonAcquired (Inactive) by Menlo Therapeutics on Nov 2019 - ceased to operate
Wikidata QIDQ104480752

Acquisitions & public offerings

Acquired by Menlo Therapeutics 2019-11

Radar intelligence

Patents

EPO16

Web history (Wayback)

Domainvynetherapeutics.com

Wikidata

QIDQ104480752

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)513368811
Statusמחוסלת מרצון — CLOSED
Corp typeישראלית חברה פרטית
Incorporated2003-01-19
Purposeלעסוק בסוגי עיסוק שפורטו בתקנון
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2013
Active charges / liens0
Registry events0
Registered addressדרך בגין 52 תל אביב - יפו